| 1 |
31527867 | A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. | 2019 |
1 |
| 2 |
29402408 | CC-223 inhibits human head and neck squamous cell carcinoma cell growth. | 2018 Feb 19 |
1 |
| 3 |
28334043 | CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo. | 2017 |
1 |
| 4 |
25855786 | CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. | 2015 Jun |
1 |
| 5 |
26177599 | A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. | 2015 Oct 1 |
2 |